Key result
Coronary microvascular dysfunction is linked to high MACE risk, HFpEF, and poor quality of life.
Why the study?
Coronary microvascular dysfunction (CMD) is emerging as a relevant cause of morbidity, mortality, and MACEs, prompting a review of its pathogenesis, diagnostics, prognostic impact, and novel therapeutic strategies.
This review highlights that coronary microvascular dysfunction is not a benign condition, but rather confers a high risk of adverse cardiovascular outcomes, including MACEs and HFpEF, emphasizing the need for comprehensive functional assessment.
CMD warrants inclusion in prognostic assessment for MACE and HFpEF; leaves open whether targeted therapies alter outcomes.
Coronary microvascular dysfunction (CMD) comprises a wide spectrum of structural and/or functional abnormalities of coronary microcirculation that can lead to myocardial ischemia. Emerging evidence has indicated that CMD is a relevant cause of morbidity and mortality and is associated with a high risk of major adverse cardiovascular events (MACEs) and heart failure with preserved ejection fraction as well as poor quality of life. This review aims to elucidate briefly the pathogenesis and diagnostic modalities of CMD and to shed light on contemporary evidence on the prognostic impact of CMD. Finally, we will provide an overview of novel emerging therapeutic strategies for CMD.
No takes yet. Share an insight, caveat, or question.
Gurgoglione et al. (2025) conducted a review in Coronary Microvascular Dysfunction (CMD). Coronary microvascular dysfunction is associated with a high risk of major adverse cardiovascular events, heart failure with preserved ejection fraction, and poor quality of life.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: